Faculty Opinions recommendation of Acute exacerbation of idiopathic pulmonary fibrosis. an international working group report.

2016 ◽  
Author(s):  
Jay H Ryu
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbation ◽  
Working Group ◽  
International Working Group ◽  
Group Report

scholarly journals Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

2016 ◽  
Vol 194 (3) ◽  
pp. 265-275 ◽  
Author(s):  
Harold R. Collard ◽  
Christopher J. Ryerson ◽  
Tamera J. Corte ◽  
Gisli Jenkins ◽  
Yasuhiro Kondoh ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbation ◽  
Working Group ◽  
International Working Group ◽  
Group Report

scholarly journals Serum decorin is a potential prognostic biomarker in patients with acute exacerbation of idiopathic pulmonary fibrosis

2018 ◽  
Vol 10 (9) ◽  
pp. 5346-5358 ◽  
Author(s):  
Takefumi Nikaido ◽  
Yoshinori Tanino ◽  
Xintao Wang ◽  
Yuki Sato ◽  
Ryuichi Togawa ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbation ◽  
Prognostic Biomarker

scholarly journals PRS49 Epidemiology of ACUTE Exacerbation Among Patients with Idiopathic Pulmonary Fibrosis in JAPAN: A Claims-Based Retrospective Study

2020 ◽  
Vol 23 ◽  
pp. S726
Author(s):  
S. Homma ◽  
T. Suda ◽  
Y. Hongo ◽  
M. Yoshida ◽  
S. Hiroi ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbation

Acute exacerbation of idiopathic pulmonary fibrosis: when bronchoalveolar lavage becomes a lethal weapon

2017 ◽  
Vol 83 (5) ◽  
Author(s):  
Gaetano Rea ◽  
Giuseppe Fiorentino ◽  
Antonio Corcione ◽  
Maurizia Lanza ◽  
Francesco Perna ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Bronchoalveolar Lavage ◽  
Acute Exacerbation

scholarly journals Impact of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Outcomes after Lung Transplantation

2016 ◽  
Vol 35 (4) ◽  
pp. S232 ◽  
Author(s):  
R. Tomic ◽  
A. Keenan ◽  
E. Dincer ◽  
H. Kim
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Transplantation ◽  
Acute Exacerbation

scholarly journals Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials

BMJ Open ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. e050004
Author(s):  
Wenjuan Wu ◽  
Lingxiao Qiu ◽  
Jizhen Wu ◽  
Xueya Liu ◽  
Guojun Zhang
Keyword(s):  
Systematic Review ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Adverse Events ◽  
Acute Exacerbation ◽  
Randomised Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Randomised Controlled

ObjectivesIdiopathic pulmonary fibrosis (IPF) has been defined as a distinctive type of chronic fibrotic disease, characterised by a progressive decline in lung function and a common histological pattern of interstitial pneumonia. To analyse the efficacy and safety of pirfenidone in the treatment of IPF, a systematic review and meta-analysis was performed.DesignThis is a meta-analysis study.ParticipantsPatients were diagnosed as IPF.InterventionsUse of pirfenidone.Primary and secondary outcomeProgression-free survival (PFS), acute exacerbation and worsening of IPF and Impact on adverse events.MeasuresThe inverse variance method for the random-effects model was used to summarise the dichotomous outcomes, risk ratios and 95% CIs.ResultsA total of 9 randomised controlled trials with 1011 participants receiving pirfenidone and 912 controls receiving placebo were summarised. The pooled result suggested a statistically significant difference inall-cause mortality after pirfenidone use, with a summarised relative ratio of 0.51 (p<0.01). Longer PFS was observed in patients receiving pirfenidone compared with those who were given placebo (p<0.01). The IPF groups presented a high incidence of adverse events with a pooled relative ratio of 3.89 (p<0.01).ConclusionsPirfenidone can provide survival benefit for patients with IPF. Pirfenidone treatment was also associated with a longer PFS, a lower incidence of acute exacerbation and worsening of IPF.

Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis

Cytokine ◽  
2013 ◽  
Vol 61 (1) ◽  
pp. 84-89 ◽  
Author(s):  
Keiji Oishi ◽  
Yuka Mimura-Kimura ◽  
Taku Miyasho ◽  
Keisuke Aoe ◽  
Yoshiko Ogata ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbation ◽  
Polymyxin B ◽  
Polymyxin B Hemoperfusion
Sign in / Sign up

Export Citation Format

Share Document